IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Completed · Phase 1

Conditions studied: Lymphoma, Non-Hodgkin, Chronic Lymphocytic Leukemia

In brief

The purpose of this study is to test the safety and tolerability of IMGN529 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL).

Key facts

Study ID

NCT01534715

Run by

ImmunoGen, Inc.

People needed

49

Starts

2012-01-01

Expected to finish

2016-07-01

Last updated by the study team

2017-12-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Relapsed or refractory NHL including tumor types: Follicular lymphoma (FL), marginal zone lymphoma (MZL)/mucosa-associated lymphoid tissue (MALT), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL).
• Adequate organ function
• ECOG ≤ 2
• Recovered or stabilized from prior treatments.

You may not qualify if…

• Allogeneic stem cell transplantation
• Pregnant or lactating females
• Known central nervous system, meningeal or epidural disease including brain metastases

Where it is running

• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• Ohio State University — Columbus, Ohio, United States
• Sarah Cannon Research Institute — Nashville, Tennessee, United States
• CTRC at UTHSCSA — San Antonio, Texas, United States
• Medical College of Wisconsin — Milwaukee, Wisconsin, United States
• Oncology Institute of Southern Switzerland — Bellinzona, Switzerland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.